These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 22568268)

  • 1. Diabetic nephropathy and multiorgan protection. Part II.
    Gluhovschi G; Gluhovschi C; Vlad A; Timar R; Bob F; Velciov S; Bozdog G; Petrica L
    Rom J Intern Med; 2011; 49(4):237-49. PubMed ID: 22568268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetic nephropathy and multiorgan protection. Part I.
    Gluhovschi GH; Gluhovschi C; Vlad A; Timar R; Bob F; Velciov S; Bozdog GH; Petrica L
    Rom J Intern Med; 2011; 49(3):163-77. PubMed ID: 22471098
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Management of Diabetic Nephropathy.
    Papademetriou V; Alataki S; Stavropoulos K; Papadopoulos C; Bakogiannis K; Tsioufis K
    Curr Vasc Pharmacol; 2020; 18(2):139-147. PubMed ID: 30961500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D protection from rat diabetic nephropathy is partly mediated through Klotho expression and renin-angiotensin inhibition.
    Eltablawy N; Ashour H; Rashed LA; Hamza WM
    Arch Physiol Biochem; 2018 Dec; 124(5):461-467. PubMed ID: 29308676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Risk and prevention of diabetic nephropathy].
    Ravera M; Re M; Deferrari G
    G Ital Nefrol; 2007; 24 Suppl 38():13-9. PubMed ID: 17922442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic nephropathy: A twisted thread to unravel.
    Dagar N; Das P; Bisht P; Taraphdar AK; Velayutham R; Arumugam S
    Life Sci; 2021 Aug; 278():119635. PubMed ID: 34015285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renin Angiotensin Aldosterone System (RAAS): its biology and drug targets for treating diabetic nephropathy.
    Zain M; Awan FR
    Pak J Pharm Sci; 2014 Sep; 27(5):1379-91. PubMed ID: 25176370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Role of Renin Angiotensin Aldosterone System Genes in Diabetic Nephropathy.
    Rahimi Z
    Can J Diabetes; 2016 Apr; 40(2):178-83. PubMed ID: 26619914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy: the role of aldosterone.
    Schjoedt KJ; Jacobsen P; Rossing K; Boomsma F; Parving HH
    Horm Metab Res; 2005 Apr; 37 Suppl 1():4-8. PubMed ID: 15918104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vitamin D protects against diabetic nephropathy: Evidence-based effectiveness and mechanism.
    Hu X; Liu W; Yan Y; Liu H; Huang Q; Xiao Y; Gong Z; Du J
    Eur J Pharmacol; 2019 Feb; 845():91-98. PubMed ID: 30287151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sodium-glucose cotransporter 2 inhibition in type 1 diabetes: simultaneous glucose lowering and renal protection?
    Cherney DZ; Perkins BA
    Can J Diabetes; 2014 Oct; 38(5):356-63. PubMed ID: 25192954
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Albuminuria: a target for treatment of type 2 diabetic nephropathy.
    de Zeeuw D
    Semin Nephrol; 2007 Mar; 27(2):172-81. PubMed ID: 17418686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diabetic Nephropathy: a Tangled Web to Unweave.
    Magee C; Grieve DJ; Watson CJ; Brazil DP
    Cardiovasc Drugs Ther; 2017 Dec; 31(5-6):579-592. PubMed ID: 28956186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Renoprotection by blockade of the renin-angiotensin-aldosterone system in diabetic and non-diabetic chronic kidney disease. Specific involvement of intra-renal angiotensin-converting enzyme activity in therapy resistance?
    Vogt L; Kocks MJ; Laverman GD; Navis G
    Minerva Med; 2004 Oct; 95(5):395-409. PubMed ID: 15467515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL.
    de Zeeuw D; Remuzzi G; Parving HH; Keane WF; Zhang Z; Shahinfar S; Snapinn S; Cooper ME; Mitch WE; Brenner BM
    Kidney Int; 2004 Jun; 65(6):2309-20. PubMed ID: 15149345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Approaches to prevention of cardiovascular complications and events in diabetes mellitus.
    Coccheri S
    Drugs; 2007; 67(7):997-1026. PubMed ID: 17488145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protective effects of aliskiren and valsartan in mice with diabetic nephropathy.
    Wang W; Qiu L; Howard A; Solis N; Li C; Wang X; Kopp JB; Levi M
    J Renin Angiotensin Aldosterone Syst; 2014 Dec; 15(4):384-95. PubMed ID: 25031296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
    Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
    J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Optimizing antihypertensive therapy in patients with diabetic nephropathy.
    Ritz E; Rychlík I; Miltenberger-Miltenyi G
    J Hypertens Suppl; 1998 Sep; 16(7):S17-22. PubMed ID: 9855027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vitamin D and diabetic nephropathy.
    Li YC
    Curr Diab Rep; 2008 Dec; 8(6):464-9. PubMed ID: 18990303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.